BioMarin to Participate in Four Upcoming Investor Conferences in March

• TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026
• Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026
• Jefferies 2026 Biotech on the Beach Summit on Tuesday, March 10, 2026
• Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026

SAN RAFAEL, Calif., Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

TD Cowen 46th Annual Health Care Conference (Boston, MA)

• Wednesday, March 4th, Alexander Hardy, President & Chief Executive Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 10:30am ET and host 1x1 meetings

Leerink 2026 Global Healthcare Conference (Miami, FL)

• Monday, March 9^th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 8:00am ET and host 1x1 meetings

Jefferies 2026 Biotech on the Bay Summit (Miami, FL)

• Tuesday, March 10^th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will host 1x1 meetings

Barclays 28^th Annual Global Healthcare Conference (Miami, FL)

• Wednesday, March 11^th, Cristin Hubbard, Executive Vice President, Chief Commercial Officer and Brian Mueller, Executive Vice President, Chief Financial Officer will participate in a fireside chat at 2:00pm ET and host 1x1 meetings

The fireside chats will be webcast live and can be accessed by visiting BioMarin's website at https://investors.biomarin.com/. A webcast replay will be available through the Company's website for a limited time following the conferences.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with multiple commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march-302695288.html

SOURCE BioMarin Pharmaceutical Inc.